In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).
This educational activity was developed by Healthed at the request of and with funding from GSK.
PM-AU-FVU-VID-230011 Approved October 2023.
Optimising Management of Acute Migraine
Heart Failure in General Practice
Carrier Screening & Medicare Rebate
The Current COVID Wave
Triple Therapy for Severe Asthma – More Than the Sum of its Parts